| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
3-Epiursolic Acid functions as a competitive inhibitor of cathepsin L, a cysteine protease implicated in tumor progression and inflammation. It demonstrates an IC50 of 6.5 μM and a Ki of 19.5 μM. Importantly, it exhibits selectivity for cathepsin L without significantly affecting cathepsin B. Beyond cathepsin L inhibition, it also acts as an inhibitor of glycogen phosphorylase, a distinct biochemical interaction not shared by all analogs.
|
|---|---|
| ln Vitro |
In vitro, 3-Epiursolic Acid is a potent and selective inhibitor of cathepsin L. Its unique C-3α stereochemistry ensures a distinct mechanistic profile compared to ursolic acid, such as mitotic spindle disruption in MCF-7 cells. It shows no obvious effect on cathepsin B, highlighting its selectivity. This compound serves as an essential HPLC reference standard for distinguishing epimers in natural product isolation.
|
| ln Vivo |
In vivo, 3-Epiursolic Acid is suggested to have anti-inflammatory activity. Research suggests it possesses antioxidant, anti-inflammatory, and antimicrobial activities, alongside cytotoxic and hepatoprotective potential. It has been investigated for its ability to regulate apoptosis and modulate oxidative stress pathways, making it relevant to cancer, liver, and metabolic disease studies. However, specific in vivo efficacy data are limited.
|
| Enzyme Assay |
For in vitro enzyme assays, the activity of 3-Epiursolic Acid is assessed by measuring its inhibition of cathepsin L and glycogen phosphorylase. For cathepsin L, a fluorogenic peptide substrate (e.g., Z-Phe-Arg-AMC) is used. The enzyme is incubated with the substrate and varying concentrations of the inhibitor. The release of the fluorescent AMC group is measured to determine the IC50 and Ki values. For glycogen phosphorylase, a similar assay using a suitable substrate is performed.
|
| Cell Assay |
For in vitro cell-based assays, the activity of 3-Epiursolic Acid can be evaluated using cancer cell lines like MCF-7 breast cancer cells. Cells are treated with the compound, and cell viability is measured using MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining. The compound's effects on cell cycle and mitotic spindle can be studied using fluorescence microscopy. Its anti-inflammatory effects can be evaluated in immune cells by measuring cytokine production.
|
| Animal Protocol |
For in vivo animal studies, 3-Epiursolic Acid is typically administered orally or intraperitoneally. To study its anticancer potential, xenograft models of cancer can be used. To study its anti-inflammatory effects, models of acute or chronic inflammation can be used. Parameters such as tumor growth, inflammatory markers, and tissue histopathology are assessed.
|
| ADME/Pharmacokinetics |
3-Epiursolic Acid has a molecular weight of 456.7. It is typically stored as a powder at -20°C. As a triterpenoid, it is expected to have poor oral bioavailability. Detailed pharmacokinetic parameters, such as half-life and tissue distribution, are not publicly available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 3-Epiursolic Acid are limited. As a natural compound, it is generally considered to have a favorable safety profile. However, comprehensive toxicological studies have not been published. The compound is used for research purposes only and is not intended for human use. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
It has been reported that 3-epiotarsolic acid is found in Scutellaria baicalensis, Sage, and other organisms with available data. It is a pentacyclic triterpenoid that coexists with its isomer oleanolic acid in a variety of plants and is abundant in fruits (such as cranberries, pears, plums, and olives), medicinal herbs, and other plants.
3-Epiursolic Acid is a research compound with no clinical trial or regulatory approval status. It is a natural product used as a research tool for studying cathepsin L inhibition and other biological activities. Its unique stereochemistry and selectivity make it a valuable compound for structure-activity relationship studies. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C30H48O3
|
|---|---|
| Molecular Weight |
456.7003
|
| Exact Mass |
456.36
|
| CAS # |
989-30-0
|
| PubChem CID |
7163177
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
556.9±50.0 °C at 760 mmHg
|
| Flash Point |
304.7±26.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
9.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
874
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~109.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (2.74 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (2.74 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
